Applied Genetic Technologies Corporation announced an update on the proposed design of an upcoming phase 2/3 trial for its X-linked retinitis pigmentosa clinical program, according to a press release.
The trial is expected to begin in the first quarter of 2021, with about 60 participants who will be randomly assigned across three arms: a group receiving a low dose of adeno-associated virus-based gene therapy, a group receiving a high dose of the therapy and an untreated control group.
The primary endpoint is based on visual sensitivity, “with a responder defined (Read more...)
Uncategorized